Glenmark Pharmaceuticals and Hikma Enter Into an Exclusive Licensing Agreement for Commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US

Glenmark Pharmaceuticals and Hikma Enter Into an Exclusive Licensing Agreement for Commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
  • Country:
  • India

(Eds: Disclaimer: The following press release comes to you under an arrangement with PR Newswire.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.